Welcome to our dedicated page for FOXO TECHNOLOGIES news (Ticker: FOXO), a resource for investors and traders seeking the latest updates and insights on FOXO TECHNOLOGIES stock.
FOXO Technologies Inc (FOXO) operates at the intersection of epigenetic science and artificial intelligence, delivering innovative solutions for life insurance underwriting and longevity research. This page serves as the definitive source for official company announcements, financial updates, and strategic developments.
Investors and industry observers will find curated coverage of earnings reports, technology partnerships, regulatory milestones, and acquisition activity. Our repository includes press releases related to FOXO Labs' biomarker discoveries and FOXO Life's insurance product innovations, providing insight into how epigenetic data transforms risk assessment models.
Key areas of focus include updates on AI-driven health analytics, strategic expansions into community health initiatives, and advancements in DNA methylation testing methodologies. All content is sourced directly from verified corporate communications to ensure reliability.
Bookmark this page for real-time access to FOXO's evolving role in reshaping insurance through longevity science. Check regularly for critical updates that demonstrate the company's progress in translating epigenetic research into commercial applications.
FOXO Technologies Inc. (NYSEAM: FOXO) has launched its beta version of the FOXO Longevity Report, a direct-to-consumer wellness product. This innovative report utilizes epigenetic biotechnology and AI to analyze saliva samples, offering health insights across metabolism, inflammation, cardiovascular health, and indulgences. By examining nearly one million sites in the epigenome, the report provides a detailed health assessment, surpassing traditional genetic analysis methods. Interim CEO Tyler Danielson emphasized the report's potential for personal health improvement and the company's commitment to advancing health outcomes through technology. The Longevity Report is now available for purchase, with early adopters receiving product upgrades and insights at no additional cost. FOXO aims to leverage extensive epigenetic data sets to optimize healthspan and lifespan.
FOXO Technologies Inc. announced the resignation of Chief Operating Officer Taylor Fay, effective April 28, 2023. Interim CEO Tyler Danielson praised Fay's leadership, stating the company benefited from his contributions. Fay expressed pride in his time at FOXO and remains supportive of the company's future. FOXO specializes in epigenetic biomarkers related to health and aging, aiming to enhance human longevity through innovative biotechnology solutions. The company applies AI to DNA methylation for health assessments, positioning itself within the life insurance industry among others.
In this announcement, FOXO emphasizes its commitment to leveraging scientific advancements for improved health outcomes, although there are inherent risks associated with the biotechnology sector.
FOXO Technologies Inc. (NYSEAM: FOXO) reported financial results for the full year 2022, emphasizing a strategic reassessment to optimize its life insurance offerings through epigenetic science. Interim CEO Tyler Danielson highlighted efforts to realign operations and reduce costs, increasing access to liquidity after selling a non-core regulated insurance entity for over $4.7 million. The company has initiated sales of the FOXO Longevity Report™ in partnership with life insurance products and established relationships with over 3,000 independent agents. A conference call scheduled for March 30, 2023, will discuss these results.
FOXO Technologies Inc. (AMEX: FOXO) is set to report its financial results for the fourth quarter and full year ended December 31, 2022, after market close on March 30, 2023. The management will host a conference call at 3:15 p.m. Central time on the same day to discuss these results and recent business updates. Interested parties can access the call via webcast or by dialing in. FOXO specializes in commercializing epigenetic biomarkers to modernize the life insurance industry, employing artificial intelligence to analyze DNA methylation for health and aging insights.
FOXO Technologies Inc. (FOXO) has partnered with AmSuisse to enhance its insurance distribution through AmSuisse’s network of over 3,000 agents across 48 states. This collaboration aims to provide life insurance products accompanied by the FOXO Longevity Report, designed to improve client longevity and well-being. FOXO's Chief Distribution Officer, Jim Grauel, expressed excitement about reaching new markets, while AmSuisse’s CEO, Josh Hamann, highlighted the program's innovative, science-based approach to life insurance for independent agents.
FOXO Technologies Inc. (NYSEAM: FOXO) has filed its Form 10-Q for the third quarter ended September 30, 2022, after initially delaying it to review the accounting treatment of certain warrants and Series A Preferred Stock. The company confirmed that the accounting treatment was appropriate. Despite macro challenges, FOXO launched its first Longevity Report and an automated epigenetic testing system while integrating with two partners. The interim CEO expressed confidence in the company's direction, emphasizing innovation and adaptability to enhance user experience. FOXO has postponed its Q3 earnings call, planning instead for a Q4 update.
FOXO Technologies Inc. has announced significant changes in its executive leadership as of November 14, 2022. Jon Sabes has been terminated as CEO and Chairman of the Board. Tyler Danielson, previously Chief Technology Officer, has been appointed Interim CEO, while Bret Barnes takes over as Chairman. The company is in the process of searching for a permanent CEO. Additionally, Steve Sabes has been terminated as COO. FOXO plans to file for an extension with the SEC for its quarterly report for the period ending September 30, 2022.
FOXO Technologies Inc. (AMEX: FOXO) announced the resignation of Chief Product Officer Erin Sharoni effective November 9, 2022. The company expressed gratitude for her leadership, particularly regarding the FOXO Longevity Report. FOXO Technologies focuses on applying epigenetic science and AI to modernize the life insurance sector through innovative products and services aimed at improving underwriting processes and consumer value.
FOXO Technologies Inc. (AMEX: FOXO) has announced the postponement of its earnings conference call, with a subsequent press release to reveal the new date and time. This delay could indicate potential issues or uncertainty regarding the company's financial performance and outlook. FOXO operates at the intersection of technology and life insurance, focusing on epigenetic longevity science aimed at improving consumer underwriting processes through innovations like the FOXO Longevity Report™.
FOXO Technologies has announced a new managing general agency agreement between its subsidiary, FOXO LIFE, and Haven Life, a subsidiary of MassMutual. This strategic partnership aims to enhance FOXO LIFE's distribution of Haven Life insurance products through independent agents. This collaboration is set to expand FOXO LIFE's market reach, leveraging Haven Life's innovative digital purchasing experience in the life insurance sector. The announcement comes ahead of the NAILBA Annual Meeting, emphasizing FOXO's commitment to modernizing life insurance through technology.
